Since the beginning of December 2017, we have tested a number of substances of particular health concern. In addition to a series of ecstasy tablets with a (very) high MDMA content, an unknown substance was identified in two tablets alongside the expected active ingredient MDMA. The hallucinogenic substance 2C-B was detected in a further two supposed ecstasy tablets. The new psychoactive substance Clephedrone (4-CMC) was identified in one sample submitted as MDMA, one as mephedrone and one as cocaine. In addition to clephedrone (4-CMC), the following cathinone derivatives were found in various samples: Methylone (bk-MDMA), Dimethylone (bk-MDDMA), 4-Chloroethcathinone (4-CEC), Methyl ethyl cathinone (4-MEC).

Current warnings December 2017